Dietary Supplement/Drug Claims Consumer Research Suggested By CSPI
This article was originally published in The Tan Sheet
FDA "should conduct consumer research as a first step in convincing Congress that many consumers do not understand the difference between structure/function claims and drug claims," Center for Science in the Public Interest Senior Staff Attorney Ilene Heller told the Public Voice for Food & Health Policy annual food policy conference March 16 in Washington, D.C. "The results of such research should be submitted to Congress together with appropriate recommendations for amendments to the law," Heller said.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC